MOESM3 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 3. mRNA expression for selected cell cycle genes in PC9GR cells before and after treatment of apatinib through RT-PCR. The experiments were performed in triplicate, and the data were presented as mean ¹ SD, ***p < 0.0001 vs. control group

MOESM6 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 6. Differentially expressed genes in VEGF pathway. A. a heat map for DEGs in any of C vs. A and D vs. C comparison. B. DEGs highlighted in VEGF pathway, red for up regulation and green for down regulation

MOESM4 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 4. Differentially expressed genes in PC9 cells and PC9GR cells

MOESM2 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 2. Differentially expressed genes in PC9GR cells after treatment with apatinib

MOESM1 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 1. Differentially expressed genes in PC9 cells before and after treatment with apatinib

MOESM5 of Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Additional file 5. Significantly enriched pathways for differentially expressed genes between PC9GR cells and PC9 cells

Figure S3 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Impact of the IL-6 cutoff level on progression-free survival (A) and overall survival (B).</p

Figure S2 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier analyses of PFS for patients with normal and elevated ({greater than or equal to}7 pg/ml) baseline IL-6 levels.</p

Figure S1 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Kaplan-Meier curves for progression-free survival in subgroups.</p

Figure S4 from Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Dynamics of IL-6 levels in the two treatment groups at different time points (A) and comparison of the IL-6 levels between the two arms at each time point (B).</p